---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-24-001326"
form_type: "8-K"
ticker: null
cik: "0001100397"
company_name: "Ayala Pharmaceuticals, Inc."
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:43:06.990773+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ayala Pharmaceuticals' CMO departs immediately; CFO agrees to leave June 25

## Summary
- Andres Guttierez, CMO and EVP, departed on March 25, 2024 upon closing of asset sale to Immunome.
- Roy Golan, CFO, agreed to depart on June 25, 2024, per agreement dated March 27, 2024.
- No replacements have been named for either departing officer.
- Departures follow the previously announced Asset Purchase Agreement with Immunome, Inc.

## SEC filing metadata
- accession: 0000929638-24-001326
- form_type: 8-K
- cik: 0001100397
- company_name: Ayala Pharmaceuticals, Inc.
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-24-001326
- JSON: https://secwatch.observer/filing/0000929638-24-001326.json
- Plain text: https://secwatch.observer/filing/0000929638-24-001326.txt

## Key facts
- Executive change
  Roy Golan departed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..
  - Action: departed
  - Role: Chief Financial Officer
  source text: the Company and Roy Golan, the Company’s Chief Financial Officer, agreed that Mr. Golan would depart the Company on June 25, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm
- Executive change
  Andres Guttierez departed as Chief Medical Officer and Executive Vice President at Ayala Pharmaceuticals, Inc..
  - Action: departed
  - Role: Chief Medical Officer and Executive Vice President
  source text: Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.